Glenmark, LVT announce approval of 2 NDAs

Glenmark and Lehigh Valley Technologies jointly announce the approval by the FDA of two New Drug Applications (NDAs) for a line of controlled substance products containing Oxycodone, signing a new agreement between Glenmark and LVT.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead master your money SME Special
moneycontrol.com

Home » News » Press Release

Dec 06, 2010, 12.30 PM | Source: Moneycontrol.com

Glenmark, LVT announce approval of 2 NDAs

Glenmark and Lehigh Valley Technologies jointly announce the approval by the FDA of two New Drug Applications (NDAs) for a line of controlled substance products containing Oxycodone, signing a new agreement between Glenmark and LVT.

Like this story, share it with millions of investors on M3

Glenmark, LVT announce approval of 2 NDAs

Glenmark and Lehigh Valley Technologies jointly announce the approval by the FDA of two New Drug Applications (NDAs) for a line of controlled substance products containing Oxycodone, signing a new agreement between Glenmark and LVT.

Post Your Comments

Share Cancel

Glenmark, LVT announce approval of 2 NDAs
Glenmark Generics Inc, USA (Glenmark), the United States subsidiary of Glenmark Generics Ltd, and Lehigh Valley Technologies (LVT) jointly announce the approval by the Food and Drug Administration of two New Drug Applications (NDAs) for a line of controlled substance products containing Oxycodone Hydrochloride (Oxycodone), along with their signing of a new Supply and Marketing Agreement between Glenmark and LVT.

The two approved NDAs provide Glenmark and LVT with manufacturing and distribution rights to the only FDA approved Oxycodone immediate release capsules and oral solution currently available in the United States.

LVT will be responsible for the manufacture of the Oxycodone product line for Glenmark’s exclusive marketing and distribution in generic form. LVT will retain exclusive marketing rights to the branded version of the Oxycodone product line. LVT will also retain exclusive marketing rights to additional strengths of the Oxycodone product line in both generic and branded forms, including but not limited to Oxycodone Hydrochloride HCl 5mg/5Ml oral solution.

According to IMS Health for the 12 month period ending September 2010, Oxycodone Hydrochloride immediate release oral solid capsule and liquid formulations represent total market sales of USD 13 million.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Glenmark, LVT announce approval of 2 NDAs

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login